163 related articles for article (PubMed ID: 37500927)
1. Serum AKR1B10 as an indicator of unfavorable survival of hepatocellular carcinoma.
Xie C; Ye X; Zeng L; Zeng X; Cao D
J Gastroenterol; 2023 Oct; 58(10):1030-1042. PubMed ID: 37500927
[TBL] [Abstract][Full Text] [Related]
2. Up-regulated aldo-keto reductase family 1 member B10 in chronic hepatitis C: association with serum alpha-fetoprotein and hepatocellular carcinoma.
Sato S; Genda T; Hirano K; Tsuzura H; Narita Y; Kanemitsu Y; Kikuchi T; Iijima K; Wada R; Ichida T
Liver Int; 2012 Oct; 32(9):1382-90. PubMed ID: 22681639
[TBL] [Abstract][Full Text] [Related]
3. A Large-Scale Multicenter Study Validates Aldo-Keto Reductase Family 1 Member B10 as a Prevalent Serum Marker for Detection of Hepatocellular Carcinoma.
Ye X; Li C; Zu X; Lin M; Liu Q; Liu J; Xu G; Chen Z; Xu Y; Liu L; Luo D; Cao Z; Shi G; Feng Z; Deng H; Liao Q; Cai C; Liao DF; Wang J; Jin J; Cao D
Hepatology; 2019 Jun; 69(6):2489-2501. PubMed ID: 30672601
[TBL] [Abstract][Full Text] [Related]
4. High expression of aldo-keto reductase 1B10 is an independent predictor of favorable prognosis in patients with hepatocellular carcinoma.
Ha SY; Song DH; Lee JJ; Lee HW; Cho SY; Park CK
Gut Liver; 2014 Nov; 8(6):648-54. PubMed ID: 25287169
[TBL] [Abstract][Full Text] [Related]
5. SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma.
Jin GZ; Yu WL; Dong H; Zhou WP; Gu YJ; Yu H; Yu H; Lu XY; Xian ZH; Liu YK; Cong WM; Wu MC
J Hepatol; 2013 Sep; 59(3):510-7. PubMed ID: 23665285
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of AKR1B10 in hepatocellular carcinoma: A systematic review and meta-analysis.
Wang Z; Pei Y; Li W; Zhang J; Liu J
PLoS One; 2022; 17(12):e0279591. PubMed ID: 36584078
[TBL] [Abstract][Full Text] [Related]
7. AKR1B10 expression characteristics in hepatocellular carcinoma and its correlation with clinicopathological features and immune microenvironment.
Ma LN; Ma Y; Luo X; Ma ZM; Ma LN; Ding XC
Sci Rep; 2024 May; 14(1):12149. PubMed ID: 38802416
[TBL] [Abstract][Full Text] [Related]
8. Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC.
Torres-Mena JE; Salazar-Villegas KN; Sánchez-Rodríguez R; López-Gabiño B; Del Pozo-Yauner L; Arellanes-Robledo J; Villa-Treviño S; Gutiérrez-Nava MA; Pérez-Carreón JI
Dig Dis Sci; 2018 Apr; 63(4):934-944. PubMed ID: 29383608
[TBL] [Abstract][Full Text] [Related]
9. Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma.
Sato S; Genda T; Ichida T; Murata A; Tsuzura H; Narita Y; Kanemitsu Y; Ishikawa S; Kikuchi T; Mori M; Hirano K; Iijima K; Wada R; Nagahara A; Watanabe S
J Gastroenterol Hepatol; 2016 Jul; 31(7):1315-22. PubMed ID: 26758591
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemistry Detects Increased Expression of Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) in Early-Stage Hepatocellular Carcinoma.
Han C; Gao L; Zhao L; Sheng Q; Zhang C; An Z; Xia T; Ding Y; Wang J; Bai H; Dou X
Med Sci Monit; 2018 Oct; 24():7414-7423. PubMed ID: 30328412
[TBL] [Abstract][Full Text] [Related]
11. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Role of Basal Serum Alpha-Fetoprotein in Patients with Hepatocellular Carcinoma Suitable for Curative Treatment.
Mazza S; Frigerio C; Alfieri D; Mauro A; Torello Viera F; Scalvini D; Barteselli C; Sgarlata C; Veronese L; Bardone M; Rovedatti L; Agazzi S; Strada E; Pozzi L; Maestri M; Ravetta V; Anderloni A
Medicina (Kaunas); 2024 Apr; 60(5):. PubMed ID: 38792876
[No Abstract] [Full Text] [Related]
13. Serum AKR1B10 predicts the risk of hepatocellular carcinoma - A retrospective single-center study.
Zhu R; Xiao J; Luo D; Dong M; Sun T; Jin J
Gastroenterol Hepatol; 2019 Dec; 42(10):614-621. PubMed ID: 31495535
[TBL] [Abstract][Full Text] [Related]
14. Identification of a role for serum aldo-keto reductase family 1 member B10 in early detection of hepatocellular carcinoma.
Han C; Gao L; Bai H; Dou X
Oncol Lett; 2018 Dec; 16(6):7123-7130. PubMed ID: 30546447
[TBL] [Abstract][Full Text] [Related]
15. Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.
Kanno M; Kawaguchi K; Honda M; Horii R; Takatori H; Shimakami T; Kitamura K; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S
J Gastroenterol; 2019 Jun; 54(6):549-557. PubMed ID: 30707282
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of 14-3-3ε, Aldo-keto Reductase Family 1 B10 and Metallothionein-1 in Hepatocellular Carcinoma.
Wu CY; Jan YJ; Ko BS; Wu YJ; Wu YJ; Liou JY
Anticancer Res; 2018 Dec; 38(12):6855-6863. PubMed ID: 30504401
[TBL] [Abstract][Full Text] [Related]
17. Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions.
Matkowskyj KA; Bai H; Liao J; Zhang W; Li H; Rao S; Omary R; Yang GY
Hum Pathol; 2014 Apr; 45(4):834-43. PubMed ID: 24656094
[TBL] [Abstract][Full Text] [Related]
18. The ratio of preoperative alpha-fetoprotein level to total tumor volume as a prognostic factor of hepatocellular carcinoma after liver transplantation.
Jiang T; Zhang XS; Pan F; Lyu SC; Wang J; Huang MX; He Q; Lang R
Medicine (Baltimore); 2021 Jul; 100(26):e26487. PubMed ID: 34190174
[TBL] [Abstract][Full Text] [Related]
19. AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases.
Schmitz KJ; Sotiropoulos GC; Baba HA; Schmid KW; Müller D; Paul A; Auer T; Gamerith G; Loeffler-Ragg J
Liver Int; 2011 Jul; 31(6):810-6. PubMed ID: 21645211
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication.
Murata A; Genda T; Ichida T; Amano N; Sato S; Tsuzura H; Sato S; Narita Y; Kanemitsu Y; Shimada Y; Hirano K; Iijima K; Wada R; Nagahara A; Watanabe S
World J Gastroenterol; 2016 Sep; 22(33):7569-78. PubMed ID: 27672277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]